

- **Name:** Junghoon Shin
 - **Current Position & Affiliation:** Samsung Medical Center
 - **Country:** Korea
-

- **Educational Background:**

- 2018 – 2022 Ph.D., Graduate School of Medical Science and Engineering, KAIST
- 2016 – 2018 M.Sc. Graduate Program in Translational Research, SNU College of Medicine
- 2009 – 2013 M.D., SNU College of Medicine
- 2007 – 2009 Premedical Course, SNU College of Natural Science

- **Professional Experience:**

- 2024 – Present Clinical Assistant Professor, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center
- 2023 – 2024 Clinical Fellow, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center
- 2022 – 2023 Clinical Fellow, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital
- 2017 Visiting Researcher, Informatics and Computational Biology Program, Ontario Institute for Cancer Research
- 2014 – 2018 Resident, Department of Internal Medicine, Seoul National University Hospital
- 2013 – 2014 Intern, Seoul National University Hospital

- **Professional Organizations:**

KBCS
KSMO
KCSG
ASCO
ESMO

- **Main Scientific Publications:**

1. **Shin J***, Park S*, Kim KH, et al. Adjuvant Pembrolizumab in Patients with Stage IIIA/N2 Non-Small Cell Lung Cancer Completely Resected after Neoadjuvant Concurrent Chemoradiation: A Prospective, Open-Label, Single-Arm, Phase 2 Trial. Cancer Res Treat 2024 (In eng). DOI: 10.4143/crt.2024.084.

2. **Shin J***, Kim J-Y*, Oh JM, et al. Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer. *Cancers* 2023;15(19):4720.
(<https://www.mdpi.com/2072-6694/15/19/4720>).
3. **Shin J**, Lee JY, Lee GW, et al. Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma. *Br J Haematol* 2023 (In eng). DOI: 10.1111/bjh.18965.
4. Byun JM, **Shin J**, Kim SA, et al. A Phase II Study to Evaluate the Efficacy of Bortezomib in Combination with Thalidomide in Treatment-Naïve Waldenstrom Macroglobulinemia Patients. *Cancer Res Treat* 2023 (In eng). DOI: 10.4143/crt.2023.681.
5. Lim L, Jang EJ, Jo JW, **Shin J**, et al. The Association Between Institutional Case Volume of Hematopoietic Stem Cell Transplantation and Mortality. *Transplant Proc* 2023;55(7):1715-1725. (In eng). DOI: 10.1016/j.transproceed.2023.05.019.
6. Kim J-Y*, **Shin J***, Ahn JS, Park YH, Im Y-H. Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. *Cancers (Basel)* 2023.
7. **Shin J***, Kim D*, Kim H-L, Choi M, Koh Y, Yoon S-S. Oncogenic effects of germline variants in lysosomal storage disease genes. *Genet Med* 2019.
8. **Shin J**, Ko YH, Oh SY, et al. Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. *Cancer Res Treat* 2019.
9. **Shin J***, Chung JH*, Kim SH, et al. Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. *Cancer Res Treat* 2018.
10. **Shin J***, Lee KS*, Yoh KA, et al. Prognostic Impact of DNA Repair Protein Expression in Non-Small Cell Lung Cancers Treated with Platinum-Based Chemotherapy and Subsequent Curative Lung Resection. *Oncology* 2018;95:20-30.
11. **Shin J**, Lee JJ, Kim K, et al. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. *Int J Hematol* 2018.
12. **Shin J***, Koh Y*, Yoon SH, et al. A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea. *Cancer Med* 2018;7:1814-23.